Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Ligand Pharmaceuticals
Thumbnail
March 03, 2023

Spotlight – What's next in Nash

The next few months will see some important mid-stage Nash results, from Viking, 89Bio, Northsea and others.

Thumbnail
July 18, 2022

Unpacking Royalty Pharma

The serial acquirer of royalty interests is coming into its own, but the secret to its success lies in cystic fibrosis.

Article image
Vantage logo
October 20, 2021

Low-key Astra hold puts spotlight on Novartis and Servier

Article image
Vantage logo
September 02, 2021

Pevonedistat could spell the end for a rare anticancer mechanism

Article image
Vantage logo
August 02, 2021

US FDA approval tracker: July 2021

Article image
Vantage logo
June 30, 2021

Go or no go? Ardelyx and Chemocentryx among those waiting FDA decisions

Big regulatory events for July include a panel for Fibrogen's roxadustat and decision time for Albireo; elsewhere, Jak inhibitor delays could persist.

Article image
Vantage logo
May 26, 2021

Vectura marks a sorry outcome for UK biotech

Article image
Vantage logo
December 23, 2020

Who will follow Curis’s clinical validation?

As Curis clinically backs a novel oncology mechanism, several companies might review their own similarly acting projects.

Article image
Vantage logo
August 12, 2020

Contingent value is back in vogue

This week another takeover included a CVR element, confirming a trend that has been gaining traction over the past year.

Article image
Vantage logo
November 26, 2019

Cymabay is out, but for Genfit the band plays on

A day after seladelpar is canned over toxicity fears elafibranor passes a safety review, but should Genfit holders worry all the same?

Article image
Vantage logo
November 01, 2019

Breaking down Beigene’s latest deal with the west

A multifaceted tie-up effectively gives Beigene a net $1.5bn fund-raising and several Amgen drugs to sell locally.

  • Load More
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

February 17, 2023

PD(L)anner – February 2023

February 09, 2023

Biopharma and Medtech Review 2022

View more...

Editor's Picks

Vantage logo
March 13, 2023

Silicon Valley Bank: biopharma’s latest crisis

Vantage logo
March 13, 2023

Pfizer rescues biotech

Vantage logo
February 28, 2023

Why Pfizer (and others) will be interested in Seagen

Vantage logo
March 04, 2023

ACC 2023 – Esperion’s outcomes win looks lacklustre

Vantage logo
March 06, 2023

T-cell receptor behemoths consolidate? Not quite

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up